# US 2008/0187952 A1 · Biomarkers of Ionizing Radiation Response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187952 A1
- Document ID: US20080187952A1
- Status: Published application
- Kind: A1
- Application number: 12/023,868
- Filed: 2008-01-31
- Published: 2008-08-07
- Earliest claimed: 2007-02-05
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Gabriela G. Cezar; Alan M. Smith
- Web page: https://patentgrep.com/patent/US20080187952A1

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/5038: {involving detection of metabolites per se}
- G01N 2800/40: Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
- Y10T 436/201666: Carboxylic acid
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention provides methods for measuring cellular response to ionization radiation (IR). The invention also provides a plurality of diagnostic and prognostic cancer biomarkers for assessing cellular response to IR.

## Claims

### Claim 1

A method for identifying a cellular metabolite or plurality of cellular metabolites differentially produced in cells exposed to ionizing radiation, the method comprising the steps of:
a. assaying a biological sample for cellular metabolites prior to and after exposure to ionizing radiation, and
b. identifying cellular metabolites having a molecular weight of from about 55 to about 3000 Daltons that are differentially produced in cells following ionizing radiation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is a patient sample.

### Claim 3 (depends on 2)

The method of claim 2, wherein the patient sample is serum, cerebrospinal fluid, blood plasma, lymph, saliva, or urine.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the cells are malignant or precancerous.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the cells are glioma cells or glioblastoma cells.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the cellular metabolite is produced in greater amounts following exposure to ionizing radiation.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the cellular metabolite is produced in greater amounts in the absence of the exposure to ionizing radiation.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the cellular metabolite is a small molecule.

### Claim 9 (depends on 1, 8)

A method according to claim 1 or claim 8 wherein cellular metabolites are assayed using a physical separation method.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the physical separation method is liquid chromatography—mass spectrometry.

### Claim 11 (depends on 1)

A method according to claim 1, wherein the cellular metabolites are produced by enzymatic activity in the phenylalanine pathway.

### Claim 12 (depends on 1)

A method according to claim 1, wherein the cellular metabolites are phenylacetate, phenylacetylglycine, 2-phenylacetamide, alpha-N-phenylacetyl-L-glutamine, phenylacetic acid, salsolinol, or serotonin.

### Claim 13 (depends on 1)

A method according to claim 1, wherein the cellular metabolites are butyrylcarnitine, L-Thyronine, glucosylgalactosyl hydroxylysine, 1-(9Z, 12Z-octadecadienoyl)-rac-glycerol, 7a-12a-Dihydroxy-3-oxo-4-cholenic acid, or 25:0 N-acyl taurine.

### Claim 14 (depends on 11, 12, 13)

A method according to claim 11, claim 12, or claim 13, wherein the cells are glioma cells or glioblastoma cells.

### Claim 15 (depends on 1)

A method according to claim 1, wherein a plurality of cellular metabolites is identified.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the plurality of identified cellular metabolites comprises a biomarker profile of cellular response to ionizing radiation.

### Claim 17 (depends on 1)

A biomarker profile of ionizing radiation produced according to the method of claim 1.

### Claim 18 (depends on 1)

A method of monitoring cellular response to ionizing radiation, the method comprising the step of identifying one or a plurality of cellular metabolites identified according to the method of claim 1 in a biological sample following exposure to ionizing radiation.

### Claim 19 (depends on 16)

A method of monitoring cellular response to ionizing radiation, the method comprising the step of identifying one or a plurality of cellular metabolites comprising a biomarker profile according to claim 16 in a biological sample.

### Claim 20 (depends on 18, 19)

The method of claim 18 or claim 19, wherein the biological sample is from an individual.

### Claim 21

A method of monitoring cellular response to ionizing radiation, the method comprising the step of measuring phenylacetate or medium-chain acylcarnitines in a biological sample exposed to a therapeutic amount of ionizing radiation.

### Claim 22

A method of monitoring glioma cell response to ionizing radiation, the method comprising the step of measuring phenylacetate in a biological sample exposed to a therapeutic amount of ionizing radiation.

### Claim 23 (depends on 21, 22)

The method of claim 21 or claim 22, wherein the biological sample is a patient sample.

### Claim 24 (depends on 23)

The method of claim 23, wherein the patient sample is serum, cerebrospinal fluid, blood plasma, lymph, saliva, or urine.

### Claim 25 (depends on 21, 22)

The method of claim 21 or 22, wherein measuring phenylacetate is performed within 24 hours of exposure to a therapeutic amount of ionizing radiation.

### Claim 26

A method for determining an individual's exposure to radiation, the method comprising measuring phenylacetate in a biological sample.

### Claim 27 (depends on 26)

The method of claim 26, wherein the individual was exposed to radiation outside of medical treatment.

### Claim 28

A method for identifying a cellular metabolite or a plurality of cellular metabolites differentially produced in cells exposed to ionizing radiation, the method comprising the steps of:
a. assaying tumor cells for cellular metabolites prior to and after exposure to ionizing radiation, and
b. identifying cellular metabolites having a molecular weight of from about 55 to about 3000 Daltons that are differentially produced in cells following ionizing radiation.

### Claim 29 (depends on 28)

The method of claim 28, wherein the tumor cells are glioma cells or glioblastoma cells.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the cellular metabolite is produced in greater amounts following exposure to ionizing radiation.

### Claim 31 (depends on 28)

The method according to claim 28, wherein the cellular metabolite is produced in greater amounts in the absence of the exposure to ionizing radiation.

### Claim 32 (depends on 28)

The method according to claim 28, wherein the cellular metabolite is a small molecule.

### Claim 33 (depends on 28, 32)

A method according to claim 28 or claim 32 wherein cellular metabolites are assayed using a physical separation method.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the physical separation method is liquid chromatography—mass spectrometry.

### Claim 35 (depends on 28)

A method according to claim 28, wherein the cellular metabolites are produced by enzymatic activity in the phenylalanine pathway.

### Claim 36 (depends on 28)

A method according to claim 28, wherein the cellular metabolites are phenylacetate, phenylacetylglycine, 2-phenylacetamide, alpha-N-phenylacetyl-L-glutamine, phenylacetic acid, salsolinol, or serotonin.

### Claim 37 (depends on 28)

A method according to claim 28, wherein the cellular metabolites are butyrylcamitine, L-Thyronine, glucosylgalactosyl hydroxylysine, 1-(9Z, 12Z-octadecadienoyl)-rac-glycerol, 7a-12a-Dihydroxy-3-oxo-4-cholenic acid, or 25:0 N-acyl taurine.

### Claim 38 (depends on 28)

A method according to claim 28, wherein a plurality of cellular metabolites is identified.

### Claim 39 (depends on 38)

A method according to claim 38, wherein the plurality of identified cellular metabolites comprises a biomarker profile of ionizing radiation.
